Li C, Li X. Advances in therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients who have experienced progression after treatment with CDK4/6 inhibitors. Onco Targets Ther. 2021;14:2929–39. https://doi.org/10.2147/OTT.S298720.

Article  PubMed  PubMed Central  Google Scholar 

Goncalves MD, Hopkins BD, Cantley LC. Phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med. 2018;379(21):2052–62. https://doi.org/10.1056/NEJMra1704560.

Article  CAS  PubMed  Google Scholar 

Glaviano A, Foo ASC, Lam HY, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https://doi.org/10.1186/s12943-023-01827-6. Published 2023 Aug 18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Leary B, Cutts RJ, Liu Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to Palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403. https://doi.org/10.1158/2159-8290.CD-18-0264.

Article  PubMed  PubMed Central  Google Scholar 

Armaghani AJ, Han HS. Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data. Breast Cancer (Dove Med Press). 2020;12:251–8. https://doi.org/10.2147/BCTT.S219436.

Article  CAS  PubMed  Google Scholar 

Piqray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Co.; January 2024.

André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA- mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.

Article  PubMed  Google Scholar 

Li A, Schleicher SM, Andre F, Mitri ZI. Genomic alteration in metastatic breast cancer and its treatment. Am Soc Clin Oncol Educ Book. 2020;40:1–14. https://doi.org/10.1200/EDBK_280463.

Article  PubMed  Google Scholar 

Truqap [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2024.

Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–70. https://doi.org/10.1056/NEJMoa2214131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23(1):85. https://doi.org/10.1186/s13058-021-01462-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Orserdu [package insert]. New York, NY: Stemline Therapeutics; January 2023.

Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol. 2022;40(28):3246–56. https://doi.org/10.1200/JCO.22.00338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu D, Weintraub MA, Garcia C, et al. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Med. 2022;11(8):1796–804. https://doi.org/10.1002/cam4.4579.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Lacouture ME, Goncalves MD, Masharani U, Aapro MS, O’Shaughnessy JA. A multidisciplinary approach to optimizing care of patients treated with Alpelisib. Breast. 2022;61:156–67. https://doi.org/10.1016/j.breast.2021.12.016.

Article  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S43–51. https://doi.org/10.2337/dc24-S003.

Article  Google Scholar 

Llombart-Cussac A, Pérez-Garcia JM, Ruiz Borrego M, et al. Preventing alpelisib-related hyperglycemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2024;71:102520. https://doi.org/10.1016/j.eclinm.2024.102520.

Article  PubMed  PubMed Central  Google Scholar 

Gallagher EJ, Moore H, Lacouture ME, et al. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer. 2024;10(1):12. https://doi.org/10.1038/s41523-024-00613-x. Published 2024 Jan 31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30(Suppl10):x21–6. https://doi.org/10.1093/annonc/mdz440.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, André F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31(8):1001–10. https://doi.org/10.1016/j.annonc.2020.05.001.

Article  CAS  PubMed  Google Scholar 

Curigliano G, Shah RR. Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology. Drug Saf. 2019;42(2):247–62. https://doi.org/10.1007/s40264-018-0778-4.

Article  CAS  PubMed  Google Scholar 

Kang S, Kim SB. HER2-low breast cancer: now and in the future. Cancer Res Treat. 2024;56(3):700–20. https://doi.org/10.4143/crt.2023.1138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hu X, Dent R, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2407086.

Article  PubMed  Google Scholar 

Enhertu [package insert]. Basking Ridge, NJ: Daiichi Sankyo Inc.; April 2024.

Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–46. https://doi.org/10.1111/cas.12966.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108. https://doi.org/10.1158/1078-0432.CCR-15-2822.

Article  CAS  PubMed  Google Scholar 

Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat. 2022;194(3):569–75. https://doi.org/10.1007/s10549-022-06660-x.

Article  CAS  PubMed  Google Scholar 

Trodelvy [package insert]. Foster City. CA: Gilead Sciences Inc; April 2024.

Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11(6):987–95. https://doi.org/10.1080/19420862.2019.1632115.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365–76. https://doi.org/10.1200/JCO.22.01002.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423–33. https://doi.org/10.1016/S